Inhibition of STAT3, FAK and Src mediated signaling reduces cancer stem cell load, tumorigenic potential and metastasis in breast cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Thakur, Ravi ^a   Trivedi, Rachana ^a   Rastogi, Namrata ^a   Singh, Manisha ^a   Mishra, Durga Prasad ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE 1; HERBACEOUS AGENT; NAPHTHOQUINONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN KINASE P60; PTK2 PROTEIN, HUMAN; SHIKONIN; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ADULT; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CANCER STEM CELL; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; MCF-7 CELL LINE; MIDDLE AGED; MULTICELLULAR SPHEROID; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR INVASION; TUMOR VOLUME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DRUGS, CHINESE HERBAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FOCAL ADHESION KINASE 1; HUMANS; MCF-7 CELLS; MIDDLE AGED; NAPHTHOQUINONES; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS PP60(C-SRC); SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; STAT3 TRANSCRIPTION FACTOR; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 84929353226     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10194     Document Type: Article

References (57)

1. Al-Ejeh, F. et al. Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis 32, 650-8 (2011).
2. Pinto, C. A., Widodo, E., Waltham, M. & Thompson, E. W. Breast cancer stem cells and epithelial mesenchymal plasticity - Implications for chemoresistance. Cancer Lett 341, 56-62 (2013).
3. Karamboulas, C. & Ailles, L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim. Biophys. Acta 1830, 2481-95 (2013).
4. Fouse, S. D. & Costello, J. F. Cancer Stem Cells Activate STAT3 the EZ Way. Cancer Cell 23, 711-3 (2013).
5. Guan, J. L. Integrin signaling through FAK in the regulation of mammary stem cells and breast cancer. IUBMB Life 62, 268-76 (2010).
6. Abhold, E. L. et al. EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells. PLoS One 7, e32459; DOI: 10.1371/journal.pone.0032459 (2012).
7. Ahmed, N., Abubaker, K., Findlay, J. & Quinn, M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr. Cancer Drug Targets 10, 268-78 (2010).
8. Tiwari, N., Gheldof, A., Tatari, M. & Christofori, G. EMT as the ultimate survival mechanism of cancer cells. Semin. Cancer Biol. 22, 194-207 (2012).
9. Liu, H. et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc. Natl. Acad. Sci. USA 107, 18115-20 (2010).
10. Sampieri, K. & Fodde, R. Cancer stem cells and metastasis. Semin. Cancer Biol. 22, 187-93 (2012).
11. Martin, T. A. & Jiang, W. G. Evaluation of the expression of stem cell markers in human breast cancer reveals a correlation with clinical progression and metastatic disease in ductal carcinoma. Oncol. Rep. 31, 262-72 (2014).
12. Andujar, I., Rios, J. L., Giner, R. M. & Recio, M. C. Pharmacological properties of shikonin - a review of literature since 2002. Planta Med. 79, 1685-97 (2013).
13. Wu, H. et al. Anticancer agent shikonin is an incompetent inducer of cancer drug resistance. PLoS One 8, e52706; DOI: 10.1371/ journal.pone.0052706 (2013)
14. Andujar, I., Recio, M. C., Giner, R. M. & Rios, J. L. Traditional chinese medicine remedy to jury: the pharmacological basis for the use of shikonin as an anticancer therapy. Curr. Med. Chem. 20, 2892-8 (2013).
15. Yang, H. et al. Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int. J. Cancer 124, 2450-9 (2009).
16. Chen, J. et al. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. Oncogene 30, 4297-306 (2011).
17. Yang, Q., Ji, M., Guan, H., Shi, B. & Hou, P. Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways. J. Clin. Endocrinol. Metab. 98, E1909-17 (2013).
18. Hou, Y., Guo, T., Wu, C., He, X. & Zhao, M. Effect of shikonin on human breast cancer cells proliferation and apoptosis in vitro. Yakugaku Zasshi 126, 1383-6 (2006).
19. Wiench, B., Eichhorn, T., Paulsen, M. & Efferth, T. Shikonin directly targets mitochondria and causes mitochondrial dysfunction in cancer cells. Evid. Based Complement Alternat. Med. 2012, 726025 (2012).
20. Eroles, P., Bosch, A., Perez-Fidalgo, J. A. & Lluch, A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat. Rev. 38, 698-707 (2012).
21. Marotta, L. L. et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 121, 2723-35 (2011).
22. Luo, M. et al. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res. 69, 466-74 (2009).
23. Chen, Y. S. et al. CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer. PLoS One 6, e28053; DOI: 10.1371/journal.pone.0028053 (2011).
24. Schober, M. & Fuchs, E. Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-beta and integrin/ focal adhesion kinase (FAK) signaling. Proc. Natl. Acad. Sci. USA 108, 10544-9 (2011).
25. Kurebayashi, J. et al. Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype. BMC Cancer 10, 568 (2010).
26. Iliopoulos, D., Hirsch, H. A., Wang, G. & Struhl, K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc. Natl. Acad. Sci. USA 108, 1397-402 (2011).
27. Kim, S. Y. et al. Role of the IL6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal 25, 961-9 (2013).
28. Kidder, B. L., Yang, J. & Palmer, S. Stat3 and c-Myc genome-wide promoter occupancy in embryonic stem cells. PLoS One 3, e3932; DOI: 10.1371/journal.pone.0003932. (2008).
29. Ura, H. et al. STAT3 and Oct-3/4 control histone modification through induction of Eed in embryonic stem cells. J. Biol. Chem. 283, 9713-23 (2008).
30. Pulaski, B. A. & Ostrand-Rosenberg, S. Mouse 4T1 breast tumor model. Curr. Protoc. Immunol. Chapter 20, Unit 20 2 (2001).
31. Chen, K., Huang, Y. H. & Chen, J. L. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol. Sin. 34, 732-40 (2013).
32. Ning, X., Shu, J., Du, Y., Ben, Q. & Li, Z. Therapeutic strategies targeting cancer stem cells. Cancer Biol. Ther. 14, 295-303 (2013).
33. Hu, Y. & Fu, L. Targeting cancer stem cells: a new therapy to cure cancer patients. Am J. Cancer Res. 2, 340-56 (2012).
34. Kawasaki, B. T., Hurt, E. M., Mistree, T. & Farrar, W. L. Targeting cancer stem cells with phytochemicals. Mol. Interv. 8, 174-84 (2008).
35. Liu, A., Yu, X. & Liu, S. Pluripotency transcription factors and cancer stem cells: small genes make a big difference. Chin. J. Cancer 32, 483-7 (2013).
36. Trosko, J. E. From adult stem cells to cancer stem cells: Oct-4 Gene, cell-cell communication, and hormones during tumor promotion. Ann. N. Y. Acad. Sci. 1089, 36-58 (2006).
37. Lu, X., Mazur, S. J., Lin, T., Appella, E. & Xu, Y. The pluripotency factor Nanog promotes breast cancer tumorigenesis and metastasis. Oncogene. 33, 2655-64 (2014).
38. Charafe-Jauffret, E. et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 16, 45-55 (2010).
39. Singh, S. et al. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in nonsmall cell lung cancer. Mol. Cancer 11, 73 (2012).
40. Nair, R. et al. c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene. 33, 3992-4002 (2014).
41. Dave, B. et al. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One 7, e30207; DOI: 10.1371/journal.pone.0030207 (2012).
42. Lee, B. Y., Timpson, P., Horvath, L. G. & Daly, R. J. FAK Signaling in Human Cancer as a Target for Therapeutics. Pharmacol. Ther.; DOI: 10.1016/j.pharmthera.2014.10.001 (2014).
43. Hatina, J. The dynamics of cancer stem cells. Neoplasma 59, 700-7 (2012).
44. Fessler, E., Dijkgraaf, F. E., De Sousa, E. M. F. & Medema, J. P. Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame? Cancer Lett. 341, 97-104 (2013).
45. th September 2014)
46. Kryczek, I. et al. IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 40, 772-84 (2014).
47. Zhao, D. et al. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene; DOI: 10.1038/onc.2014.257 (2014).
48. Korkaya, H., Liu, S. & Wicha, M. S. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J. Clin. Invest. 121, 3804-9 (2011).
49. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-15 (2008).
50. Sulzmaier, F. J., Jean, C. & Schlaepfer, D. D. FAK in cancer: mechanistic findings and clinical applications. Nat. Rev. Cancer. 14, 598-610 (2014).
51. Bolos, V., Gasent, J. M., Lopez-Tarruella, S. & Grande, E. The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther. 3, 83-97 (2010).
52. Orgaz, J. L. et al. Diverse matrix metalloproteinase functions regulate cancer amoeboid migration. Nat. Commun. 5, 4255 (2014).
53. Lakka, S. S. et al. Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene 21, 5601-8 (2002).
54. Kaur, P. et al. A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer 12, 120 (2012).
55. Tao, K., Fang, M., Alroy, J. & Sahagian, G. G. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer 8, 228 (2008).
56. Oh, K. et al. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL6 trans-signaling in a murine model. Breast Cancer Res. 15, R79 (2013).
57. Mitra, S. K., Lim, S. T., Chi, A. & Schlaepfer, D. D. Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model. Oncogene 25, 4429-40 (2006).